As key players in next generation sequencing and multi omics solutions, Novogene is pleased to introduce the Element AVITI24™ system at its European lab in Munich, expanding our local sequencing capabilities. This state-of-the-art sequencing platform delivers flexible workflows with accurate sequencing, that is capable of supporting projects from pilot to mid-scale studies for diverse genomic applications.

The Element AVITI24 system features dual independent flow cells, enabling researchers to run projects simultaneously or independently. The platform supports multiple sequencing strategies, from PE75 and PE150 to PE300, making it particularly well-suited for specialised applications that require shorter or longer read configurations. AVITI24 supports small to mid-scale projects and provides researchers with greater freedom in tailoring sequencing strategies to their specific needs.

Key advantages include:

• High data quality with reduced duplication rates, delivering reliable results across applications.
• Sequencing flexibility, supporting PE75 and PE300 read lengths, offering more options for pilot studies or niche research questions.
• Balanced throughput, bridging small to mid-scale sequencing projects with efficiency and flexibility.
• Local sequencing in our Munich lab ensures faster turnaround and simplified logistics for EU customers.

“This new addition reinforces Novogene’s commitment to innovation and flexibility, enabling faster turnaround times and more versatile sequencing strategies to support a growing range of research needs across Europe” said Tingting Zhou, VP at Novogene Europe.

In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, including genomic, transcriptomic, microbial, and single-cell sequencing. Localised deployment in European labs enables tailored support while maintaining global standards of excellence.